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The Notch signaling pathway plays a crucial role in neurodevelopment and in adult brain homeostasis. 
We aimed to further investigate Notch pathway activity in bipolar disorder (BD) and schizophrenia 
(SCZ) by conducting a pathway analysis. We measured plasma levels of Notch ligands (DLL1 and 
DLK1) using enzyme immunoassays in a large sample of patients (SCZ n=551, BD n=246) and 
healthy controls (HC n=639). We also determined Notch pathway related gene expression levels by 
microarray analyses from whole blood in a subsample (SCZ n=338, BD n=241 and HC n=263). We 
found significantly elevated Notch ligand levels in plasma in both SCZ and BD compared to HC. 
Significant gene expression findings included increased levels of RFNG and KAT2B (p<0.001), and 
decreased levels of PSEN1 and CREBBP in both patient groups (p<0.001). RBPJ was significantly 
lower in SCZ vs HC (p<0.001), and patients using lithium had higher levels of RBPJ (p<0.001). We 
provide evidence of altered Notch signaling in both SCZ and BD compared to HC, and suggest that 
Notch signaling pathway may be disturbed in these disorders. Lithium may ameliorate aberrant Notch 






Schizophrenia (SCZ) and bipolar disorder (BD) are severe mental disorders that have prompted 
extensive research as they are among the leading causes of worldwide disability
1,2
. The 
neurodevelopmental hypothesis for SCZ suggests that the neuroanatomical defects associated with 
SCZ are caused by dysregulation of brain development
3
. In BD, brain morphological alterations are 
more subtle, but these together with behavioral changes prior to onset of illness support 
neurodevelopmental abnormalities also for BD
4
. In addition to developmental abnormalities, 
accelerated grey matter decline, aberrant brain connectivity and biochemical changes in the adult brain 
may indicate neurodegenerative processes in SCZ
5,6
; this may also be present in BD, albeit 
substantially less prominent
7
.   
Notch signaling is well known as a master regulator of neural stem cells and neural development, and 
orchestrates nervous system development and patterning by regulating neurogenesis, axonal growth, 
synaptogenesis and predisposing neurons to apoptosis also in the adult brain
8
. These facts make it a 
pertinent candidate for exploration in psychotic disorders. The Notch signaling pathway was first 
associated with SCZ through genetic findings linking the NOTCH4 gene to SCZ in British parent-
offspring trios
9
, and later confirmed by larger genome wide association studies
10
. Initial studies 
investigating Notch in BD were inconclusive
11,12
, however, in 2012 we found increased gene 
expression of NOTCH4 in BD
13
.  
In addition to being important in regulating neural cell proliferation, differentiation, and neural cellular 
growth
8
, Notch is a crucial contributor in adaptive and innate immune responses
14
. Notch and its 
ligands (e.g. delta-like 1, DLL1) have also been implicated in endothelial cell dysregulation and 
vascular inflammation
15,16
 as well as macrophage activation
17
, and is involved in the interaction 
between immune cells and the brain during ischemic stroke. This may be relevant also in relation to 
severe psychotic disorders as immune-pathogenic mechanisms have been implicated in SCZ and BD, 






Based on the emerging significance of neuro-inflammation and immunogenetics in SCZ and 
BD, we hypothesized that Notch signaling components in inflammatory cells, both as a proxy for CNS 
tissues, but also representing important cells that could modulate different neural processes, would be 
dysregulated. Thus, we aimed to characterize the Notch signaling pathway in patients with SCZ, BD 
and healthy controls (HC) by conducting a pathway analysis on the mRNA level in whole blood, as 
well as investigating plasma levels of secreted Notch ligands. Our secondary aim was to investigate 
whether potential alterations in Notch pathway mRNA expression or secreted ligands are associated 






Demographics and clinical characteristics 
Socio-demographic and clinical characteristics of the participants are shown in Table 1. The plasma 
protein cohort and the whole blood mRNA cohort showed the same differences between SCZ, BD and 
HC groups with the exception of one clinical characteristic: SCZ patients had higher CDSS scores in 
whole blood cohort, but not in the plasma protein cohort. The main differences between patients and 
HC were age, ethnicity and sex. 
  
Plasma levels of Notch ligands  
The plasma levels of the secreted Notch ligands and group comparisons are summarized in Table 2. 
Patients had significantly higher plasma levels of DLL1 compared to HCs, with SCZ having 
significantly higher levels than BD after controlling for age and gender. DLK1 levels showed 
nominally significant increase in both patient groups compared to HC with no differences between BD 
and SCZ.  
Gene expression in whole blood  
The mRNA expression of Notch pathway genes are summarized in Figures 1 and 2 and Table 3, and 
nominally significant findings (0.001 < p < 0.05) in Supplementary Table 1. Effect size estimates were 
small in general with the highest value on 0.16 for KAT2B. Compared to HC, both SCZ and BD had 
increased levels of RFNG and KAT2B, and decreased levels of PSEN1 and CREBBP mRNA 
expression. In addition, the SCZ group had increased DTX3L and decreased RBPJ, CTBP and HDAC 
mRNA expression compared to HC (Figure 1). The main significant differences between SCZ and BD 
were lower LFNG and increased NOTCH2 in SCZ vs BD (Table 3 and Supplementary figure 1). 
 
Role of medication 
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We found that patients using lithium (n=35) had significantly higher RBPJ expression compared to 
patients not taking lithium (n=366, p<0.001) (Supplementary table 2). As the BD group had higher 
levels of RBPJ mRNA we also controlled for diagnosis. Our result remained significant after 
controlling for diagnosis (t=3.35 p=0.001 F=5.63 n=400) and when investigating lithium in the BD 
group alone (t=3.51 p=0.001 F=3.42 n=148). This association does not seem to be dosage dependent, 
as we observed no correlation between serum levels of lithium and RBPJ expression. We found 
nominally significant effects of antipsychotics and mood stabilizers on DLK1 levels, and a weak dose 





In the present study we evaluated circulating levels of secreted Notch ligands from plasma and mRNA 
expression of Notch family members and transcripts that may influence Notch signaling in whole 
blood in a large population of patients with SCZ and BD as well as in heathy controls. We found 
significant differences in the concerted regulation of Notch mRNA species between patients and 
controls, in addition to an increase in circulating levels of secreted Notch ligands. Our main findings 
include (i) raised levels of DLL1, which is a soluble Notch ligand with potential inhibiting effect on 
Notch signaling, (ii) down-regulation of PSEN1 and RBPJ (SCZ), potentially impairing intracellular 
Notch signaling, and (iii) up-regulation of RFNG mRNA, which may inhibit ligand-receptor 
interactions, further impairing Notch signaling.  
DLL1 and DLK1 are soluble Notch ligands that are cleaved from their respective 
transmembrane forms by ADAM proteins, and likely inhibit Notch signaling
19,20
. Thus, the increased 
plasma levels of DLL1 and potentially DLK1 in SCZ and BD could reflect attenuated Notch activity 
in these disorders. We have previously identified elevated ADAM17 mRNA levels in BD, suggesting 
that ADAM17 may be involved in the heightened shedding of Notch ligands in our patient group
21
. 
Fringe proteins modulate Notch signaling by sensitizing notch receptors to delta ligands and 
attenuating notch-serrate interactions
22
. Radical fringe (RFNG) is abundantly expressed in the rat brain, 
and has been found to negatively modulate Notch signaling
23
. Both SCZ and BD patients had 
significantly elevated RFNG expression compared to HC. This further supports a possible impediment 
in Notch signaling in patients vs. controls. PSEN1- controlled γ-secretase activity is essential for 
Notch signaling as it releases the Notch intracellular domain (NICD) that subsequently enters the 
nucleus to regulate gene activity. Thus, decreased PSEN1 expression in patients also favors attenuated 
Notch signaling, but may also have multiple functions outside of the γ-secretase complex
24
. The 
implications of enhanced expression of DTX3L are less clear. DTX3L belongs to the deltex family, 
which can facilitate intracellular trafficking of the NICD from the membrane to the nucleus. However, 






In the nucleus, the RBP-J protein enables NICD to bind to DNA and regulate the expression of 
notch target genes (HES and HEY). SCZ patients had decreased RBPJ mRNA expression compared to 
HC. RBPJ deletion in mouse embryonic brain causes neural stem/progenitor cells to prematurely 
differentiate into neurons thus depleting the neuronal stem cell population
26
. There is also evidence 
indicating that RBP-J is necessary for hippocampal-dependent learning and memory in mice
27
. Thus, a 
shift towards downregulation could hamper proliferation in the brain and interfere with hippocampal 
functions. The downregulated co-repressors (i.e. CTBPs and HDACs) and upregulated co-activator 
KAT2B could imply a shift in favor of increased target gene transcription especially in SCZ vs controls. 
However, as the mRNA expression of RBPJ is downregulated, the significance of these alterations is 
unclear, possibly reflecting compensatory mechanisms. Furthermore, these transcriptional regulators 
are not restricted to Notch signaling and could be related to other signaling pathways
28
. In contrast to 
our finding of decreased HDAC1/2 in SCZ, a recent smaller study demonstrated increased HDAC1 
mRNA in blood leukocytes and in the hippocampus and prefrontal cortex of patients with SCZ who 
were subjected to early life stress
29
.  
Activation of the Notch signaling pathway induces transcription of target genes (HES and HEY). Hes 
and hey proteins predominantly act as transcriptional repressors
30
 and, depending on cellular context
31
, 
impede cell differentiation, and prompt cell proliferation also in the adult brain
26
. We did not observe 
altered expression of target genes in this study, thus our finding of an attenuated pattern of Notch 
signaling pathway should be interpreted with some caution. 
We show for the first time in a naturalistic study that patients taking lithium had higher levels 
of RBPJ expression compared to patients not medicated with lithium but using other psychotropic 
medication. This finding is in line with a previous study that proposed that lithium may activate the 
Notch pathway through the inhibition of glycogen synthase kinase-3β
32
. 
Our finding of a possibly hampered Notch signaling may seem at odds with the enhanced T 
cell response and chronic low grade systemic inflammation in SCZ and BD. However, the role of the 
adaptive immune system and T cell-mediated immune responses in these patients are still unclear, 
10 
 
with some studies favoring a TH2 shift at least in SCZ
33,34
. Notch has emerged as an important 
regulator of TH-cell differentiation
35
 and stimulation with Notch ligands, including DLL1, promotes a 
TH1 phenotype which may be inhibited by soluble DLL1
36
. Thus, our finding of increased plasma 
DLL1 and hampered Notch signaling as reflected by decreased RBPJ, is compatible with an altered T 
cell function potentially favoring development of Th2 cells. A recent meta-analysis suggested a shift 
towards a TH2 phenotype in SCZ based on circulating levels of typical TH1 and TH2 cytokines while 
in vitro studies favored a TH1 response in the patients. Thus, the role of Notch on T-cell mediated 
immune responses in the psychiatric disorders needs further study. 
There are some limitations to the current study. Firstly, using whole blood as proxy for the 
brain has limitations, especially when we take into consideration that the Notch signaling pathway is 
almost exclusively dependent on cell-cell interaction. However, current technology does not yet enable 
us to investigate gene expression in vivo in the brain. We are thus dependent on either post-mortem 
studies which are limited by artificial changes in gene expression, or alternatively, evaluation of easily 
accessible tissues that may reflect processes in the brain to a certain degree
37
. Secondly, the use of 
whole blood does not necessarily reflect the levels in various leukocyte subsets such as T cells and 
monocytes. Third, due to the naturalistic nature of our study most patients were using a combination of 
psychotropic medication which prevented exploration of medication in monotherapy. Fourth, the 
patients were not completely matched with controls in relation to age, ethnicity and sex, but these 
factors were adjusted for in the statistical analyses.  
In conclusion, we demonstrate altered Notch signaling in whole blood in SCZ compared to 
HC. Although less clear, our results also indicate altered Notch signaling in BD compared to HC. 
Further, we show an association between the use of lithium and Notch pathway activation. The 
demonstrated pattern of Notch molecules suggest that the Notch signaling pathway may be 
compromised in patients compared to controls. There is emerging evidence from rodent studies that 
Notch signaling is important in adult brain, and partakes in the regulation of adult neural stem cell 
migration, morphology, synaptic plasticity and survival of neurons
8
. Future studies should be aimed at 
11 
 
further exploring the Notch signaling pathway in severe mental disorders, and investigate if therapy 





The present study is part of the Norwegian Centre for Mental Disorders Research, University of Oslo 
and Oslo University Hospital, and collaborating Norwegian hospitals
13
. The study is approved by the 
Regional Committee for Medical Research Ethics and the Norwegian Data Inspectorate and all 
research was performed in accordance with these guidelines and regulations. We obtained written 




 We included patients in the study if they had DSM-IV diagnoses of schizophrenia spectrum disorders 
or bipolar spectrum disorders, IQ > 70, and age between 18 and 65 years (for details see
13
). We 
randomly selected healthy controls without a prior history of severe psychiatric disorders (or in any of 
their first-degree relatives), or substance/alcohol abuse/dependency from the same catchment area 
from the National Population Registry (www.ssb.no) (for details see
13
). For the present analyses, we 
included patients and controls if they had no coexisting autoimmune or inflammatory disease, cancer 
or ongoing infections, were not using anti-inflammatory drugs, and had C-reactive Protein (CRP) 
levels below 20 mg/L. 
Clinical Assessments: The clinical assessment and diagnostic interviews were carried out by a team of 
psychologists and physicians who were trained until satisfactory inter-rater reliability was obtained
38,39
. 
We used the Structured Clinical Interview for DSM-IV Axis I Disorders
40
 to obtain diagnoses. We 
evaluated clinical symptoms using the Young Mania Rating Scale (YMRS)
41
, Inventory of Depressive 
Symptoms (IDS)
42
, Calgary Depression Scale for Schizophrenia (CDSS)
43
 and Positive and Negative 
Syndrome Scale (PANSS)
44
. Global functioning and symptom load was measured with the Global 
Assessment of Functioning (GAF), split version. The scale has two measures reflecting functioning 
(GAF-F) and symptom load (GAF-S)
45
.   
Plasma protein assessment 
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DLL1 and DLK1 were measured in duplicate using commercially available antibodies (R&D Systems, 
Abingdon, UK) in a 384 format using a combination of a SELMA (Jena, Germany) pipetting robot and 
a BioTek (Winooski, VT, USA) dispenser/washer. Absorption was read at 450 nm with wavelength 
correction set to 540 nm using an ELISA plate reader (Bio-Rad, Hercules, CA, USA). Intra- and inter-
assay coefficients of variation were 3.9% and 3.7% for DLL1 and 5.0% and 8.4% for DLK1, 
respectively. We observed no diurnal variation for DLL1 and DLK1: in a smaller group of HC (n=13) 
blood was collected at 4 time-points within 24 hours (mean intra-individual CV±SD was 5.8±5.2%, 
p=0.27 for DLL1; and CV±SD=5.8±6.4%, p=0.86 for DLK1). Further, we found no postprandial 
variation for DLL1 and DLK1 (n=13, fasting vs. non-fasting; mean intra-individual CV±SD was 
11.1±7.6%, p=0.15 for DLL1 and CV±SD = 9.8±11.0%, p=0.84 for DLK1). Detection limits were 10 
pg/mL and 25 pg/mL for DLL1 and DLK1, respectively, as defined as 3xSD of assay buffer (n=10). 
RNA isolation and microarray analysis 
RNA isolation: Blood samples were collected using Tempus Blood RNA Tubes. Total RNA was 
extracted with ABI PRISM 6100 Nucleic Acid PrepStation and TEMPUS 12-port RNA Isolation Kit 
according to manufacturer’s protocol. High-Capacity cDNA Reverse Transcription Kit was used for 
reverse transcription of 1 µg RNA. 
Global Transcriptomics Analyses: We selected 49 Notch pathway related genes using the Kyoto 
Encyclopedia of Genes and Genomes database (http://www.genome.jp/kegg/pathway.html, hsa04330, 
version date 5/9/17). In addition, we included HEY1 as it is a well-recognized Notch signaling 
pathway target gene 
30
. For each sample 200 ng of total RNA was biotin labelled and amplified using 
the Illumina TotalPrep-96 RNA Amplification Kit (Thermo Fisher, Waltham, MA, USA). Global 
analysis of gene expression was performed with Illumina HumanHT-12 v4 Bead Chip (Illumina, San 
Diego, CA, USA) consisting of more than 47 000 probes (ie. transcripts). For this purpose, 842 
samples (263 HC, 338 SCZ and 241 BD) passed labeling and scanning. Raw microarray scan files 
were exported using the Illumina GenomeStudio software and loaded into R for downstream analysis 
using specific packages provided by BioConductor 
46
. Lumi was used to detect outliers
47
.  ComBat 
14 
 
from the SVA R package was used to correct for technical batch effects, like RNA extraction batch, 
RNA extraction method, DNase treatment batch, cRNA labelling batch and chip hybridization 
48
. 
Further quality control, quantile-normalization and log2-transformation were done using Limma
49
. 
Association between medication and protein/mRNA 
We used the defined daily dose (DDD) of psychotropic medications, which is the assumed average 
maintenance dose per day for a drug used for its main indication in adults, to investigate associations 
between medication and proteins/mRNA. We calculated the dose relative to DDD for antipsychotics, 
mood stabilizers and antidepressants according to the guidelines from the World Health Organization 
Collaborating Center for Drug Statistics Methodology (https://www.whocc.no/atcdd), and used serum 
concentration levels for lithium. We selected key Notch signaling pathway related genes whose 
expression was significantly altered in our analyses (PSEN1, RBPJ and RFNG) in addition to plasma 
proteins.  
Statistical analysis 
Plasma proteins: We used the SPSS software package for Windows, version 24.0 for the statistical 
analyses of demographic data and plasma proteins. We assessed data normality using the 
Kolmogorov-Smirnov and Shapiro-Wilk tests. As distributions were skewed, we used the Kruskal-
Wallis test, the Mann-Whitney U test and the chi-square test to investigate differences in demographic 
data and plasma proteins between groups. Associations between medication and proteins/mRNA were 
investigated by Spearman’s Rank correlation test. We controlled for age and sex in linear regression 
models. We inspected the histogram and the normal P-P plot of the regression standard residuals. In 
case of skewed distribution of the residuals we repeated our analyses using ln transformation of the 
dependent variable, and then by removing outliers defined as above -3 and below 3 studentized deleted 
residuals saved from the regression analyses.  
 Global Transcriptomics: Analysis was performed on batch-adjusted log2-transformed values. We 
used the R software environment to investigate group differences in mRNA expression. We fitted a 





, and we used its expression level to adjust for differences in time of blood sampling 
and circadian rhythm between patients and HC. 
Medication: We used ANCOVA to explore the effect of medication while controlling for age, sex and 
other medication groups. 
Correction for multiple testing: We corrected for multiple testing according to the Bonferroni method. 
Alpha was set at p < 0.001 for our main microarray analyses (investigating 49 genes), and at p < 0.03 
for the two plasma proteins. Our secondary analyses investigating the effects of medication were 
explorative in nature, and we also applied Bonferroni to correct for these analyses separately from the 
main analyses. Alpha for the secondary analyses was thus set at p < 0.003 (correcting for 20 tests). 
Data Availability 
The datasets generated and analyzed during the current study are not publicly available due to 
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Figure 1 legend 
Summary of significant and nominally significant findings in Notch pathway mRNA expression 
between the schizophrenia and the healthy control group after controlling for age, gender and Bmal1. 
Results are given as p-values, adjusted for multiple testing, where significant results are indicated in 
red/dark blue (for increased/decreased mRNA expression) and nominally significant results (0.001 < p 
< 0.05) are shown as pink/light blue (for increased/decreased mRNA expression). Non-significant 
results are depicted as boxes with white background. The figure is based on the Notch signaling 
pathway in the KEGG database (hsa04330, version date 5/9/17). Hey1 is included by the authors due 




Figure 2 legend 
Summary of significant and nominally significant findings in Notch pathway mRNA expression 
between the bipolar disorder and the healthy control group after controlling for age, gender and Bmal1. 
Results are given as p-values, adjusted for multiple testing, where significant results are indicated in 
red/dark blue (for increased/decreased mRNA expression) and nominally significant results (0.001 < p 
< 0.05) are shown as pink/light blue (for increased/decreased mRNA expression). Non-significant 
results are depicted as boxes with white background. The figure is based on the Notch signaling 
pathway in the KEGG database (hsa04330, version date 5/9/17). Hey1 is included by the authors due 
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Table 1. Demographic and clinical characteristics of participants. 
Parameters 
Plasma (Notch ligand) cohort Whole blood (mRNA) cohort 
SCZ 
(N = 551) 
BD 
(N = 246) 
HC 




(N = 338) 
BD 
(N = 241) 
HC 
(N = 263) 
Post Hoc  
Analysis 
Male sex, N (%) 334 (60.6) 97 (39.4) 364 (57.0) SCZ > HC > BD 275 (61.5) 90 (39.5) 144 (54.8) SCZ > HC > BD 
Ethnicity (Cauc. %) 444 (80.6) 213 (86.6) 629 (98.4) HC > BD > SCZ 228 (90.1) 140 (94.6) 208 (100) HC > BD > SCZ 
Medication N(%):         
   Antipsychotics 510 (84.6) 167 (66.0) - SCZ > BD 234 (92.5) 114 (77.0) - SCZ > BD 
   Lithium 12 (2.0) 51 (20.2) - BD > SCZ 3 (1.2) 32 (21.6) - BD > SCZ 
   Antidepressants 179 (31.5) 95 (38.8) - BD > SCZ 35 (13.8) 66 (44.6) - BD > SCZ 
   Mood stabilizers 56 (9.3) 87 (34.4) - BD > SCZ 78 (30.8) 57 (38.5) - BD > SCZ 
Age (years) 27 (13) 29 (18) 31 (13) BD, HC > SCZ 29 (14) 35 (20) 31.0 (13) BD, HC >SCZ 
DOI (years) 4 (8) 4 (10) - BD > SCZ 4 (9) 5 (13) - BD > SCZ 
PANSS total score 62 (22) 44 (13) - SCZ > BD 64 (24) 45 (14) - SCZ > BD 
YMRS total score 3 (9) 2 (5) - SCZ > BD 3 (9) 2 (6) - SCZ > BD 
IDS total score 17 (19) 17 (16) - NS 18 (18) 15 (16) - NS 
CDSS total score 5 (8) 4 (6) - NS 5 (7) 3 (7) - SCZ > BD 
GAF-S 40 (15) 57 (16) - BD > SCZ 40 (14) 54 (17) - BD > SCZ 
GAF-F 42 (14) 51 (19) - BD > SCZ 42 (15) 50 (17) - BD > SCZ 
Abbreviations: SCZ = Schizophrenia; BD = Bipolar Disorder; HC = Healthy Controls; Cauc.= Caucasians; NS = Non-Significant; DOI=Duration of illness; 
PANSS=Positive and Negative Syndrome Scale; YMRS=Young Mania Rating Scale; IDS=Inventory of Depressive Symptoms; CDSS= Calgary Depression 
Scale for Schizophrenia; GAF-S = Global Assessment of Functioning - Symptom Scale; GAF-F = Global Assessment of Functioning - Function Scale. 
Categorical data are given as percent in brackets, while continuous data are given as median with interquartile range. Post hoc analysis is performed using 
Pearson Chi-square for categorical data, and Mann-Whitney U tests for continuous data. Differences between groups are significant when p<0.05. 
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Table 2. Differences between groups for plasma markers of Notch pathway after controlling for age and gender. 
plasma 
ligands 
M(IQR) SCZ vs. HC BD vs. HC SCZ vs. BD 
SCZ BD HC df t F df t F df t F 
DLL1 5 (1.8) 4.7 (1.6) 4.5 (1.3) 1232 8.8*** 32.01*** 889 3.26** 10.81*** 848 3.00** 9.13*** 
DLK1 186 (170) 188 (164) 180 (149) 1243 2.23* 10.62*** 893 2.00* 11.38*** 854 0.08 9.06*** 
*p < 0.05   **p < 0.03   ***p < 0.001 
Abbreviations: M=median; IQR=interquartile range; SCZ=schizophrenia; BD=bipolar disorder; HC=healthy controls; DLL1= Delta-like protein 1; DLK1= 
Delta Like Non-Canonical Notch Ligand 1. 
ANCOVA using linear regression models. Results are significant if p<0.03, and nominally significant if 0.03<p<0.05 (Bonferroni correction). 
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Table 3. Significant differences between patients and controls in Notch signaling pathway gene mRNA expression after controlling for age and gender. 
 Genes specificity 
SCZ vs. HC BD vs. HC SCZ vs. BD 
B B B 
Receptor and Cytoplasm 
LFNG +++ -.01 .07** -.09*** 
RFNG +++ .11*** .07*** .03 
NOTCH2 +++ .01 -.04** .06*** 
DTX3L +++ .05*** .00 .05** 
PSEN1 ++ -.03*** -.02*** -.01 
Nucleus 
KAT2B ++ .16*** .13*** .03 
CREBBP + -.10*** -.09*** -.01 
CTBP1 ++ -.03*** -.01 -.02* 
CTBP2 ++ -.03*** -.01 -.02** 
HDAC1 ++ -.08*** -.04* -.04* 
HDAC2 ++ -.06*** -.05* -.01 
RBPJ + -.07*** -.01 -.06** 
*p < 0.05   **p < 0.01   ***p < 0.001  
Specificity: + (unspecific, involved in many pathways), ++ (involved in up to 3 additional pathways e.g. Wnt, NF-kappa), +++ (exclusively Notch pathway 
related gene). 
Abbreviations: SCZ=Schizophrenia; BD=Bipolar disorder; HC=Healthy controls; B=Unstandardized regression coefficient. 
Gene names are listed according to the HUGO Gene Nomenclature Committee. 
Results are given as effect size estimates from the linear regression analysis after correction for age, sex and BMAL1 expression. Results are significant if 
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Supplementary Table 1. Nominally significant differences (0.001 < p < 0.05) between patients and 
controls in Notch signaling pathway gene mRNA expression after controlling for age and gender. 
 Genes specificity 
SCZ vs. HC BD vs. HC SCZ vs. BD 
B B B 
Receptor and Cytoplasm 
MFNG +++ -.05** -.03* -.01 
LFNG +++ .01 .02* -.02 
RFNG +++ .02** .02** .00 
DTX1 +++ .02* .01 .02 
NOTCH1 +++ -.04 -.08** .04 
DTX2 +++ .01 .02* -.02 
DTX2 +++ -.04* -.03 -.01 
PSEN1 ++ -.03** -.03** .00 
PSEN2 ++ -.01 -.02* .01 
APH1B +++ .04** .03 .01 
DVL1 ++ .01 -.01 .02* 
DVL1 ++ -.01 .00 -.01* 
DVL2 ++ -.02* -.02 .00 
NCSTN +++ .00 -.05** .05** 
Nucleus 
CIR +++ -.01 .05* .05* 
CTBP1 ++ .01 .03** -.02 
KAT2A ++ -.04* .02 -.05** 
HES1 ++ .01 .02* -.01 
NCOR2 +++ .01 .01* .00 
NCOR2 +++ -.03 .02 -.05** 
RBPJ +++ -.01 .00 -.01* 
RBPJ +++ -.01* -.02** .01 
*p < 0.05   **p < 0.01    
Specificity: + (unspecific, involved in many pathways), ++ (involved in up to 3 additional pathways e.g. 
Wnt, NF-kappa), +++ (exclusively Notch pathway related gene). 
Abbreviations: SCZ=Schizophrenia; BD=Bipolar disorder; HC=Healthy controls; B=Unstandardized 
regression coefficient. 
Gene names are listed according to the HUGO Gene Nomenclature Committee. The genes represent 
probes, and are different from the probes used in Table 1. 
Results are given as effect size estimates from the linear regression analysis after correction for age, 




Supplementary Table 2. Associations between daily defined dose of medication, Notch ligand levels 











    
   Antipsychotics 603 .06 .06 299 .08 .00 .05 
   Lithium 54 .16 .10 31 .11 -.12 .06 
   Mood stabilizers 142 .08 .03 101 .05 -.20 -.14 
   Antidepressants 30 .15* -.04 120 .18 .03 -.10 










   
   Antipsychotics 690 124 1.87 2.08* 348 53 .75 -1.18 .10 
   Lithium 63 751 -.91 -.36 35 366 -.52 4.46*** -1.57 
   Mood stabilizers 145 669 -.40 2.38* 101 300 -.32 1.30 -.33 
   Antidepressants 248 566 .35 .11 135 266 .51 .94 -.16 
*p < 0.05 ***p < 0.001 
Abbreviations: DDD = daily defined dose; DLL1= delta like canonical Notch ligand 1; DLK1= 
Delta Like Non-Canonical Notch Ligand 1; yes=using the specified medication; no=not using the 
specified medication. Gene names are listed according to the HUGO Gene Nomenclature 
Committee. 
We used serum concentration of lithium instead of DDD. 
Associations and group effects are given as t from analyses of covariance with age, gender and 











Supplementary Figure 1 Summary of significant and nominally significant findings in Notch pathway mRNA expression between the schizophrenia 
and the bipolar disorder group after controlling for age, gender and Bmal1. 
Results are given as p-values, adjusted for multiple testing, where significant results are indicated in red/dark blue (for increased/decreased mRNA 
expression) and nominally significant results (0.001 < p < 0.05) are shown as pink/light blue (for increased/decreased mRNA expression).  
 
